The prostate cancer workup has been rebuilt around imaging, precision, and patience. The Atlanta specialist walks through what happens after the number comes back high, and why the modern answer looks nothing like your father's.

Courtesy Advanced Urology // Dr. Jitesh Patel at the practice's
Courtesy Advanced Urology // Dr. Jitesh Patel at the practice's Snellville, Georgia flagship.

THE NUMBER ARRIVES without ceremony. A routine physical, a blood draw you barely remember, and then a line in your patient portal: PSA 5.2, with a small flag beside it. You do what everyone does. You search it. Within four minutes you have read the words biopsy, cancer, and incontinence, and your afternoon is gone.

Take a breath. The distance between an elevated PSA and any of those words is longer than the internet suggests, and it runs through some of the best clinical research of the past decade. What that research shows is a workup transformed. Twenty years ago, a urologist confronting a PSA of 5.2 had blunt instruments: a blood test that could not distinguish cancer from a swollen prostate, and a biopsy that sampled tissue on a grid, blind, hoping to hit whatever might be there. The tools have since caught up to the stakes. Today the same number triggers a sequence built on imaging, targeting, and risk stratification, and every step of it generates information the last generation of patients never had.

Few physicians have watched that transformation from a better vantage point than Dr. Jitesh Patel, the founder and president of Advanced Urology in metro Atlanta, where the full modern pathway, from scan to diagnosis to treatment planning, runs under one roof.

The scan comes first now

Start with what PSA actually is: a protein made by prostate tissue. All prostate tissue. Cancer raises it, but so does inflammation, so does benign enlargement, so does a long weekend ride on a bike saddle. The test is a smoke detector, not a fire report. The clinical question was never whether to pay attention to it. The question was what to do next.

For most of the test's history, next meant needles. Then came PRECISION, a multicenter randomized trial published in The New England Journal of Medicine that reordered the sequence. Men with elevated PSA received a multiparametric MRI before anyone reached for a biopsy needle. The results changed practice on two fronts at once. In 28 percent of the men, the scan showed no suspicious lesion, and under the trial protocol they moved to monitoring instead of immediate sampling. Among the men whose scans did show something, targeted biopsies aimed at the lesion found clinically significant cancer in 38 percent, against 26 percent for the traditional blind approach, while cutting detection of the indolent, slow-growing kind by more than half.

Read that again, because both halves matter. The scan finds more of the cancer that needs finding, and it finds less of the kind that does not. In diagnostics, that combination is rare. It is the difference between casting a wider net and casting a smarter one.

At Advanced Urology, that principle has hardened into infrastructure. The practice operates its own imaging centers alongside its clinics, and its physicians fuse the MRI with real-time micro-ultrasound during the biopsy itself, so the needle is steered to the suspicious region as the physician works rather than aimed by feel and geometry. The scan, the radiology review, and the biopsy decision happen inside one system, in days, instead of migrating across three referral networks over a month. For a patient staring at a flagged lab value, the compression of that timeline is not a convenience. It is the difference between two weeks of clarity and six weeks of dread.

The biopsy question nobody asks

If the imaging does point to a biopsy, there is a decision embedded in the procedure that most men never hear about until they are on the table: the route the needle takes.

The traditional path runs through the rectal wall. It is fast, it is familiar, and it passes through territory that is decidedly not sterile, which is why post-biopsy infection has always been the complication urologists watch for. The newer alternative goes through the skin of the perineum under local anesthetic, an approach that has migrated from the operating room into the office over the past several years.

Which is better? Researchers have now run three randomized trials trying to settle it, and the honest answer is that the contest ended in something closer to a draw than either camp expected. The PREVENT trial, in European Urology, found the transperineal route produced zero infections without any antibiotics, but also found the transrectal route matched that record when antibiotic prophylaxis was targeted to each patient's resistance profile. A second randomized comparison found no significant difference either. And the TRANSLATE trial, published in The Lancet Oncology in 2025, offered the most useful conclusion of all: the earlier trials were likely underpowered to detect a gap, because serious infections have become genuinely rare by either route when the procedure is done well. Both approaches, it bears noting, find cancer equally well.

So the route is not a verdict handed down by the literature. It is a fit question: your infection history, your antibiotic exposures, your anatomy. That is a conversation with a urologist who knows your chart, and it is one Dr. Patel approaches with unusual seriousness about antibiotic stewardship. Writing in the physician forum KevinMD this spring, he described a patient whose recurrent urinary tract infections had bred an E. coli strain resistant to fifteen antibiotics, a resistance record documented across fourteen consecutive urine cultures. A physician who has watched resistance accumulate culture by culture does not treat prophylaxis decisions as paperwork. Every exposure is a withdrawal from an account that does not refill.

When the answer is to watch, closely

Now the hardest scenario. The biopsy finds cancer. For many men, what follows is the most counterintuitive conversation in modern urology, because for low-risk, slow-growing disease, the guideline-backed first move is often not surgery and not radiation. It is active surveillance, and the name is precise. This is not waiting. It is a structured clinical program: PSA testing on a set schedule, repeat imaging, repeat biopsy at defined intervals, with curative treatment ready the moment the disease shows its first sign of ambition.

The evidence behind it has matured from promising to formidable. A study published in JAMA in 2024 followed more than 2,000 men with localized prostate cancer enrolled in active surveillance. A decade after diagnosis, 49 percent had required no treatment at all, their disease stable under monitoring. Fewer than 2 percent had developed metastatic disease. Fewer than 1 percent had died of prostate cancer. Ten years, two thousand men, and the disease held at the gate.

For carefully selected low-risk patients, active surveillance can help avoid or delay treatment while maintaining careful clinical monitoring.

That philosophy is written into the patient guidance at Advanced Urology, which offers a full range of prostate cancer evaluation and treatment options and presents surveillance as a first-line path for appropriately selected low-risk disease. Matching the intensity of the response to the biology of the tumor is the entire discipline.

And when the biology does call for treatment, the menu has widened well beyond the binary of surgery or radiation, with newer focal approaches designed to treat the tumor while sparing the tissue around it. Staging has sharpened too. PSMA PET imaging, which lights up prostate cancer cells specifically, can reveal spread earlier than conventional scans, so the treatment plan is matched to the true extent of the disease before the first decision is locked in.

The bottom line

An elevated PSA is the beginning of a sequence, not the end of one. Each step in the modern pathway exists to add information before anything irreversible happens. So ask the questions the pathway is built to answer. Does an MRI come before my biopsy? If a biopsy is needed, which route fits my history? And if a diagnosis comes back, what does my specific risk category say about surveillance versus treatment? A workup built on that much information is the strongest position a patient has ever been in. The number on the portal is where it starts. It is nowhere near where it ends.

Advanced Urology treats patients across metro Atlanta, including Snellville, Alpharetta, Sandy Springs, and Johns Creek. Dr. Jitesh Patel, its founder and president, trained at Temple University School of Medicine and Thomas Jefferson University Hospital and is board certified by the American Board of Urology.